

SERVICES PORTFOLIO



CONTACT US AT:

PANGAEA ONCOLOGY
Laboratorio de Oncología
Hospital Universitari Dexeus
Consultas Externas. Despacho -1.7
C/Sabino de Arana 5-19,
08028 Barcelona

Samples and assays:

+34 935 460 119
+34 935 460 121

lab@panoncology.com
www.panoncology.com



OCTOBER 2023

MOLECULAR TESTING OF TUMOR TISSUE SAMPLES

— NUCLEIC ACID EXTRACTION

Macrodissection and DNA extraction from FFPE tissue

Macrodissection and RNA extraction from FFPE tissue

— COMBINED STUDIES

SOLID TUMOR (Recommended for LUNG, MELANOMA, BREAST and other Solid tumors)
CS-T-001
NGS Somatic QIaseq DNA Custom Extended Panel (30 genes)

 Genes: *ALK, ARID1A, BRAF, CDK4, CDK6, EGFR, ERBB2, ERBB4, FAT1, FGFR1, FGFR2, FGFR3, IDH1, IDH2, KEAP1, KIT, KRAS, MET, MYC, NFE2L2, NRAS, PDGFRA, PIK3CA, POLD1, POLE, RET, ROS1, SETD2, STK11, TP53*
nCounter RNA Pangaea Solid Tumor Panel*

 Fusions: *ALK, FGFR1,2,3, NRG1, NTRK1, RET, ROS1*

 Splicing variant: *METΔ14, EGFRvIII*

 Gene expression analysis: *ALK, ATM, BARD1, BID, BRCA1, BRCA2, CCNE1, CD274, CD4, CD8A, CDK2, EGFR, FGFR1,2,3, FOXP3, GZMM, IFNG, KRAS, NRG1, NTRK1,2,3, PDCD1, PTEN, RET, ROS1, STK11, TP53*
CS-T-002
Combined study CS-T-001 and PD-L1 IHC

*The nCounter RNA Pangaea Solid Tumor Panel could be replaced by the NGS RNA Fusion XP Lung Panel (ask for prices)

UROTHELIAL carcinoma study
CS-T-003
NGS Somatic QIaseq DNA Custom Extended Panel (30 genes)
nCounter RNA Pangaea Urothelial Carcinoma Panel

 Fusions: *FGFR2 and FGFR3*
Identification of the variants: *FGFR2-BICC1, FGFR2-CASP7, FGFR3ex17-TACC3ex10*
FGFR3ex17-TACCex11, FGFR3-BAIAP2L1
COLON study
CS-T-004
KRAS, BRAF, NRAS sequencing (NGS Custom Panel) (19 genes)

 Genes: *ALK, BRAF, CDK4, CDK6, EGFR, ERBB2, ERBB4, FGFR1, IDH1, IDH2, KIT, KRAS, MET, NRAS, PDGFRA, PIK3CA, ROS1, STK11, TP53*
Mismatch Repair (MMR) status (IHC)

 Genes: *MLH1, MSH2, MSH6, PMS2*
GIST study
***c-KIT, PDGFR* sequencing (NGS Custom Panel) (19 genes)**

— MULTIGENIC MOLECULAR PANELS

<p>NGS Somatic QIAsEq DNA Custom Extended Panel (30 genes) Genes: <i>ALK, ARID1A, BRAF, CDK4, CDK6, EGFR, ERBB2, ERBB4, FAT1, FGFR1, FGFR2, FGFR3, IDH1, IDH2, KEAP1, KIT, KRAS, MET, MYC, NFE2L2, NRAS, PDGFRA, PIK3CA, POLD1, POLE, RET, ROS1, SETD2, STK11, TP53</i></p>
<p>NGS RNA Fusion XP Lung Panel (13 genes) Fusions: <i>ALK, BRAF, EGFR, FGFR1,2,3, MET, NRG1, NTRK1,2,3, RET, ROS1</i> Splicing variant: <i>METΔ14</i></p>
<p>NGS Somatic QIAsEq DNA Repair Genes Panel (28 genes) Genes: <i>APC, ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CDKN2A, CHEK2, CTNNA1, EPCAM, FANCA, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PIK3CA, PMS2, POLD1, POLE, PTEN, RAD51C, RAD51D, STK11, TP53</i></p>
<p>nCounter RNA Pangaea Solid Tumor Panel Fusions: <i>ALK, FGFR1,2,3, NRG1, NTRK1, RET, ROS1</i> Splicing variants: <i>METΔ14, EGFRvIII</i> Gene expression analysis: <i>ALK, ATM, BARD1, BID, BRCA1, BRCA2, CCNE1, CD274, CD4, CD8A, CDK2, EGFR, FGFR1,2,3, FOXP3, GZMM, IFNG, KRAS, NRG1, NTRK1,2,3, PDCD1, PTEN, RET, ROS1, STK11, TP53</i></p>
<p>nCounter RNA Pangaea Urothelial Carcinoma Panel Fusions: <i>FGFR2 and FGFR3</i> Identification of the variants: <i>FGFR2-BICC1, FGFR2-CASP7, FGFR3ex17-TACC3ex10, FGFR3ex17-TACCex11, FGFR3-BAIAP2L1</i></p>
<p>PROSIGNA Genetic prognostic signature for breast cancer</p>

— INDIVIDUAL GENE MUTATIONS (TaqMan® allelic discrimination qPCR assay)

EGFR exon 19 del and EGFR exon 21 (L858R, L861Q) mutations
EGFR exon 19 del, EGFR exon 21 (L858R, L861Q) and EGFR exon 20 T790M mutations
EGFR exon 20 resistance mutation T790M
EGFR exon 20 resistance mutation C797S
KRAS hotspot mutations (codons 12, 13 and 61)
BRAF hotspot mutations (V600E, V600K, V600R)
PIK3CA hotspot mutations (codons 542, 545 and 1047)
One hotspot mutation (EGFR, KRAS, BRAF, PIK3CA)

— SPLICING VARIANTS AND FUSIONS

<i>ALK-EML4</i> by RT-PCR (variants 1, 2 and 3)
<i>ALK-EML4</i> by RT-PCR (one known variant)
<i>MET</i> splicing variants 7/8-14
<i>EGFR</i> vIII splicing variant
<i>MET</i> splicing variant 14

ANATOMIC PATHOLOGY

— ANATOMICAL PATHOLOGY DIAGNOSIS

Anatomical pathology diagnosis (H&E and 4 IHC analysis)
Confirmation of anatomical pathology diagnosis (Previous AP report required)

— MAIN FISH ASSAYS*

HER-2/neu amplification**
<i>ALK</i> fusions**
<i>ROS1</i> fusions
<i>RET</i> fusions
<i>MET</i> amplification
<i>EGFR</i> amplification
<i>KRAS</i> amplification
<i>NTRK1</i> fusions
<i>NTRK2</i> fusions
<i>NTRK3</i> fusions
<i>FGFR1</i> fusions
<i>FGFR1</i> amplification

FGFR2 fusions
FGFR2 amplification
FGFR3 fusions
FGFR3 amplification
BCL2 fusions
BCL6 fusions
NRG1 fusions
MYC fusions
MYC amplification
1p/19q loss

* Ask for other IHC or FISH assays if required

** FDA approved

— **MAIN PRONOSTIC AND PREDICTIVE IMMUNOHISTOCHEMISTRY (IHC) ASSAYS***

ALK (D5F3) **
PDL1 (22C3)
Mismatch Repair (MMR) status (MLH1, MSH2, MSH6, PMS2)
MET (SP44)

* Ask for other IHC or FISH assays if required

** FDA approved

EXTERNALIZED SERVICES

ONCOPDO 3D Organoid Test (Invitrocue)
Oncotype DX
Foundation ONE CDx

MOLECULAR TESTING OF TUMOR LIQUID BIOPSY SAMPLES

— NUCLEIC ACID EXTRACTION

cfDNA extraction from liquid biopsies

cfRNA extraction from liquid biopsies

DNA extraction from white blood cells

— COMBINED STUDIES

CS-BL-001 (Recommended for all type of tumors)
NGS Somatic QIAseq DNA Custom Panel (19 genes)

 Genes: *ALK, BRAF, CDK4, CDK6, EGFR, ERBB2, ERBB4, FGFR1, IDH1, IDH2, KIT, KRAS, MET, NRAS, PDGFRA, PIK3CA, ROS1, STK11, TP53*
nCounter RNA Pangaea Solid Tumor Panel for liquid biopsies (6 genes)

 Fusions: **ALK, NRG1, NTRK1, RET, ROS1*

 Splicing variants: *METΔ14*
**More frequently found fusions*

— MULTIGENIC MOLECULAR PANELS

NGS Somatic QIAseq DNA Custom Panel (19 genes)

 Genes: *ALK, BRAF, CDK4, CDK6, EGFR, ERBB2, ERBB4, FGFR1, IDH1, IDH2, KIT, KRAS, MET, NRAS, PDGFRA, PIK3CA, ROS1, STK11, TP53*
NGS Somatic QIAseq DNA Custom Extended Panel (30 genes)

 Genes: *ALK, ARID1A, BRAF, CDK4, CDK6, EGFR, ERBB2, ERBB4, FAT1, FGFR1, FGFR2, FGFR3, IDH1, IDH2, KEAP1, KIT, KRAS, MET, MYC, NFE2L2, NRAS, PDGFRA, PIK3CA, POLD1, POLE, RET, ROS1, SETD2, STK11, TP53*
nCounter RNA Pangaea Solid Tumor Panel for Liquid Biopsies (6 genes)

 Fusions: **ALK, NRG1, NTRK1, RET, ROS1*

 Splicing variants: *METΔ14*
**More frequently fusions*

— **INDIVIDUAL GENE MUTATIONS** (TaqMan® allelic discrimination qPCR assay)

<i>EGFR</i> exon 19 del and <i>EGFR</i> exon 21 (L858R, L861Q) mutations
<i>EGFR</i> exon 19 del, <i>EGFR</i> exon 21 (L858R, L861Q) and <i>EGFR</i> exon 20 T790M mutations
<i>EGFR</i> exon 20 resistance mutation T790M
<i>EGFR</i> exon 20 resistance mutation C797S
<i>KRAS</i> hotspot mutations (codons 12, 13 and 61)
<i>BRAF</i> hotspot mutations (V600E, V600K, V600R)
<i>PIK3CA</i> hotspot mutations (codons 542, 545 and 1047)
One hotspot mutation (<i>EGFR</i>, <i>KRAS</i>, <i>BRAF</i>, <i>PIK3CA</i>)

— **SPLICING VARIANTS AND FUSIONS**

<i>ALK-EML4</i> by RT-PCR (variants 1, 2 and 3)
<i>ALK-EML4</i> by RT-PCR (one known variant)
<i>MET</i> splicing variants 7/8-14
<i>MET</i> splicing variant 14
<i>EGFR</i> VIII splicing variant

**GERMLINE MOLECULAR
TESTING ASSOCIATED
WITH INHERITED
PREDISPOSITION
SYNDROMES**

— **MULTIGENIC MOLECULAR PANELS**

NGS QIAseq Inherited Cancer Panel (28 genes, germline)

Genes: *APC, ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CDKN2A, CHEK2, CTNNA1, EPCAM, FANCA, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PIK3CA, PMS2, POLD1, POLE, PTEN, RAD51C, RAD51D, STK11, TP53*

— **IMMUNOHISTOCHEMISTRY (IHC) ASSAYS (Recommended for Lynch syndrome)**

Mismatch Repair (MMR) status (*MLH1, MSH2, MSH6, PMS2*)*

*Sample required: FFPE Block

EXTERNALIZED SERVICES

CentoVision Panel (Inherited Diseases)

SERVICES PORTFOLIO



CONTACT US AT:

PANGAEA ONCOLOGY
Laboratorio de Oncología
Hospital Universitari Dexeus
Consultas Externas. Despacho -1.7
C/Sabino de Arana 5-19,
08028 Barcelona

Samples and assays:

+ 34 935 460 119
+ 34 935 460 121

lab@panoncology.com
www.panoncology.com

